HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aveeno Faces Class Actions Over “Naturals” Claims

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson’s Aveeno brand is the focus of two pending class-action suits filed in Connecticut and New York that call into question claims for the brand’s Natural Protection sunscreens and Active Naturals personal-care line, respectively. Both complaints allege the brand liberally uses the term “natural” for its products when they contain a number of synthetic ingredients.

You may also be interested in...

Waiting For FDA: Federal Courts Debate Stays Of 'Natural' Class Actions

Mayer Brown attorney Dale Giali discusses the "natural" litigation landscape, where litigants increasingly are sparring over the appropriateness of stays in light of FDA's comment-gathering initiative launched in 2015.

J&J Agrees To $6.75M Aveeno Active Naturals Class Settlement

The firm failed in motions to dismiss plaintiff claims and block class certification in a suit alleging that Aveeno Active Naturals products are falsely advertised because they contain synthetic ingredients. Meanwhile, class certification was granted recently in a separate case concerning Aveeno Baby "natural" claims, which could portend another settlement to come.

J&J Affirms M&A Strategy For Consumer Biz With Vogue International Buy

Johnson & Johnson wins a reported bidding war for Vogue International, picking up the popular OGX brand and other "salon-heritage" hair-care lines with natural overtones. The move is consistent with the firm's stated intention to grow its consumer business in part through targeted M&A.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts